文献速递脊柱关节炎

银屑病关节炎孕妇早产风险及危险因素:瑞典、丹麦和挪威协作队列研究

Preterm birth in women with psoriatic arthritis: what are the risks and risk factors? A collaborative cohort study from Sweden, Denmark and Norway.
PubMed 文献 · RMD Open · 2025-10-05

该协作队列研究链接三国风湿病临床登记与出生登记,纳入2006–2021年688例PsA妊娠与6880例对照妊娠(1:10匹配)。PsA妊娠早产率7.8% vs 对照4.5%,aOR 1.80(95%CI 1.29–2.51);妊娠期联合使用bDMARD与csDMARD和/或糖皮质激素者风险显著升高(aOR 4.44,95%CI 2.07–9.50),而bDMARD单药治疗未见风险升高(aOR 0.73,95%CI 0.22–2.42)。孕前高疾病负荷与风险升高相关;孕早期停用bDMARD者早产比例21% vs 继续使用超过孕早期者10%(基于少量事件)。

要点

  • PsA妊娠早产风险较对照升高80%(aOR 1.80,95%CI 1.29–2.51)。
  • 妊娠期bDMARD联合csDMARD和/或糖皮质激素者早产风险显著升高(aOR 4.44)。
  • bDMARD单药治疗(主要为TNF抑制剂)未显示早产风险升高(aOR 0.73)。

核心结论

  • PsA妊娠较对照妊娠早产风险增加80%,抗风湿联合治疗及孕前高疾病负荷为危险因素,孕早期停用bDMARD进一步增加风险,部分PsA妊娠应考虑为高危妊娠。

研究设计与样本

  • 链接瑞典、丹麦和挪威风湿病临床登记与出生登记,识别2006–2021年PsA妊娠与对照妊娠,按年龄、产次、国家和出生年份1:10匹配。

主要发现

  • PsA妊娠早产54/688(7.8%)vs 对照妊娠312/6880(4.5%),aOR 1.80(95%CI 1.29–2.51)。
  • 妊娠期暴露于bDMARD联合csDMARD和/或糖皮质激素者早产aOR 4.44(95%CI 2.07–9.50),bDMARD单药治疗者aOR 0.73(95%CI 0.22–2.42)。
  • 孕前高疾病负荷与早产风险升高相关。
  • 孕早期停用bDMARD者早产比例21% vs 继续使用超过孕早期者10%(基于少量事件)。
  • 风险估计基本不受产次、吸烟和体重指数影响。

关键数值与推荐

  • PsA妊娠vs对照妊娠早产aOR 1.80(95%CI 1.29–2.51)。
  • 妊娠期bDMARD联合csDMARD和/或糖皮质激素暴露vs对照妊娠早产aOR 4.44(95%CI 2.07–9.50)。
  • 妊娠期bDMARD单药治疗暴露vs对照妊娠早产aOR 0.73(95%CI 0.22–2.42)。
  • 孕早期停用bDMARD者早产比例21% vs 继续使用超过孕早期者10%。

临床怎么用

  • 对有PsA的孕妇,应关注妊娠期抗风湿联合治疗及孕前高疾病负荷等早产危险因素。
  • 研究结果支持将部分PsA妊娠视为高危妊娠。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate risk and to identify risk factors for preterm birth in pregnant women with psoriatic arthritis (PsA) in relation to maternal characteristics, treatment and disease activity, both before and during pregnancy. METHODS: We linked clinical rheumatology registers to medical birth registers in Sweden, Denmark and Norway and identified PsA pregnancies and control pregnancies 2006-2021, matched 1:10 on age, parity, country and birth year. Adjusted ORs (aORs) for preterm birth in PsA pregnancies vs control pregnancies were calculated overall and stratified by maternal characteristics, antirheumatic treatment and disease load (9 months before and during pregnancy). RESULTS: We observed 54 preterm births among 688 PsA pregnancies (7.8%) versus 312 among 6880 control pregnancies (4.5%); aOR, 95% CI: 1.80, 1.29 to 2.51. The risk estimate was largely unaffected by parity, smoking and body mass index. PsA pregnancies exposed to a combination of biologic and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and/or glucocorticoids during pregnancy had a markedly increased risk of preterm birth compared with control pregnancies (4.44, 2.07 to 9.50), whereas exposure to biological DMARD (bDMARD) monotherapy (primarily tumour necrosis factor inhibitors) had not (0.73, 0.22 to 2.42). High disease load before pregnancy was associated with increased risk. The proportion of preterm birth was higher in those stopping bDMARD during the first trimester (21%) opposed to those continuing past the first trimester (10%) based on few events. CONCLUSION: We identified an 80% increased risk of preterm birth in PsA pregnancies compared with control pregnancies. Antirheumatic combination therapy during and high disease load before pregnancy constituted risk factors. Discontinuing bDMARD treatment in early pregnancy further increased the risk. Our findings support that a subgroup of PsA pregnancies should be considered high-risk pregnancies.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Secher AEP, Granath F, Remaeus K, et al. Preterm birth in women with psoriatic arthritis: what are the risks and risk factors? A collaborative cohort study from Sweden, Denmark and Norway. RMD Open. 2025. PMID: 41052892. doi:10.1136/rmdopen-2025-005614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。